GLUE Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
9.0M
+113.0%
4.2M
+51.4%
2.8M
-78.2%
12.8M
-45.0%
23.2M
Cost of Revenue
0
0
0
0
0
Gross Profit
9.0M
+113.0%
4.2M
+51.4%
2.8M
-78.2%
12.8M
-45.0%
23.2M
Operating Expenses
58.1M
+7.1%
54.2M
+3.3%
52.5M
+14.8%
45.7M
+18.1%
38.7M
R&D
48.0M
+8.8%
44.1M
+5.0%
42.0M
+14.5%
36.7M
+19.7%
30.7M
SG&A
10.1M
-0.4%
10.2M
-3.3%
10.5M
+16.0%
9.1M
+12.0%
8.1M
Operating Income
-49130000
+1.8%
-50034000
-0.6%
-49715000
-50.8%
-32975000
-112.0%
-15554000
EBITDA
-47216000
+1.6%
-48005000
-0.8%
-47627000
-54.2%
-30880000
-130.0%
-13429000
Net Income
-43397000
+2.5%
-44503000
+3.5%
-46135000
-70.4%
-27081000
-120.3%
-12295000
EPS (Basic)
$-0.43
+4.4%
$-0.45
+16.7%
$-0.54
-63.6%
$-0.33
-120.0%
$-0.15
EPS (Diluted)
$-0.43
+4.4%
$-0.45
+16.7%
$-0.54
-63.6%
$-0.33
-120.0%
$-0.15
Shares (Diluted)
101.5M
+1.6%
99.9M
+17.9%
84.7M
+2.8%
82.4M
+0.3%
82.2M
Monte Rosa Therapeutics (GLUE) โ€” Financials